X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Six policy solutions to help patients afford their insulin

By Holly Campbell  |    April 9, 2019
Dramatic improvements in how we treat diabetes have transformed the lives of patients, but too many struggle to afford their insulin and other medicines at the pharmacy counter. Due to...   Read More

PhRMA comments on OIG proposed rule to reform the rebate system

By Holly Campbell  |    April 8, 2019
Today, PhRMA submitted comments on the Department of Health & Human Services (HHS) Office of Inspector General (OIG) proposed rule, “Removal of Safe Harbor Protection for Rebates Involving...   Read More

Fact Check: How the Part B International Pricing Index model threatens patient access

By Nicole Longo  |    March 29, 2019
Since the Department of Health and Human Services (HHS) released the Part B International Pricing Index (IPI) model late last year, there have been a number of inaccurate claims floating around...   Read More

OIG proposed rule could help strengthen the Part D market

By Holly Campbell  |    March 28, 2019
Patients should share in the $166B in rebates and discounts biopharmaceutical companies pay to insurance companies, the government, pharmacy benefit managers and other entities in the supply chain...   Read More

Rebate rule would help ensure seniors with diabetes don’t pay more for their medicine than their insurer

By Holly Campbell  |    March 25, 2019
Misaligned incentives in Medicare Part D are increasing costs for seniors with diabetes. While insurers negotiate larger and larger rebates with biopharmaceutical companies each year, seniors...   Read More

Bipartisan lawmakers urge Administration to rethink proposed changes to six protected classes policy

By Tom Wilbur  |    March 22, 2019
At the end of 2018, the Centers for Medicare & Medicaid Services (CMS) introduced a dangerous proposed rule that would weaken the Medicare Part D six protected classes policy. The six protected...   Read More

New analysis finds Average Sales Price system has led to significant cost savings for Medicare and seniors

By Nicole Longo  |    March 7, 2019
When Congress created the Medicare Part D program as part of the Medicare Modernization Act of 2003 (MMA), it also implemented changes to Part B to make it market based with the creation of the...   Read More

New “Prescription for Medicare” campaign focuses on impacts of wrong and right solutions for Medicare

By Juliet Johnson  |    March 6, 2019
Today, we are launching the “Prescription for Medicare” campaign which focuses on ensuring that changes made to Medicare are the right prescription for seniors. There’s a lot of talk in Washington...   Read More

New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis

By Holly Campbell  |    February 14, 2019
New research by three Milliman actuaries explores the dynamics underlying the relationship between Medicare Part D plan premiums and sharing rebates directly with beneficiaries at the pharmacy...   Read More

In survey, PhRMA member companies highlight impact of IPI on R&D

By Katie Verb  |    February 5, 2019
One of the biggest myths regarding the administration’s proposed International Pricing Index (IPI) Model is that it will have little to no effect on biomedical research and development (R&D)....   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates